TY - JOUR
T1 - Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
AU - Choudhury, Hira
AU - Pandey, Manisha
AU - Yin, Tan Hui
AU - Kaur, Taasjir
AU - Jia, Gan Wei
AU - Tan, S. Q.Lawrence
AU - Weijie, How
AU - Yang, Eric Koh Sze
AU - Keat, Chin Guan
AU - Bhattamishra, Subrat Kumar
AU - Kesharwani, Prashant
AU - Md, Shadab
AU - Molugulu, Nagasekhara
AU - Pichika, Mallikarjuna Rao
AU - Gorain, Bapi
N1 - Publisher Copyright:
© 2019
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Multidrug resistance (MDR) is one of the key barriers in chemotherapy, leading to the generation of insensitive cancer cells towards administered therapy. Genetic and epigenetic alterations of the cells are the consequences of MDR, resulted in drug resistivity, which reflects in impaired delivery of cytotoxic agents to the cancer site. Nanotechnology-based nanocarriers have shown immense shreds of evidence in overcoming these problems, where these promising tools handle desired dosage load of hydrophobic chemotherapeutics to facilitate designing of safe, controlled and effective delivery to specifically at tumor microenvironment. Therefore, encapsulating drugs within the nano-architecture have shown to enhance solubility, bioavailability, drug targeting, where co-administered P-gp inhibitors have additionally combat against developed MDR. Moreover, recent advancement in the stimuli-sensitive delivery of nanocarriers facilitates a tumor-targeted release of the chemotherapeutics to reduce the associated toxicities of chemotherapeutic agents in normal cells. The present article is focused on MDR development strategies in the cancer cell and different nanocarrier-based approaches in circumventing this hurdle to establish an effective therapy against deadliest cancer disease.
AB - Multidrug resistance (MDR) is one of the key barriers in chemotherapy, leading to the generation of insensitive cancer cells towards administered therapy. Genetic and epigenetic alterations of the cells are the consequences of MDR, resulted in drug resistivity, which reflects in impaired delivery of cytotoxic agents to the cancer site. Nanotechnology-based nanocarriers have shown immense shreds of evidence in overcoming these problems, where these promising tools handle desired dosage load of hydrophobic chemotherapeutics to facilitate designing of safe, controlled and effective delivery to specifically at tumor microenvironment. Therefore, encapsulating drugs within the nano-architecture have shown to enhance solubility, bioavailability, drug targeting, where co-administered P-gp inhibitors have additionally combat against developed MDR. Moreover, recent advancement in the stimuli-sensitive delivery of nanocarriers facilitates a tumor-targeted release of the chemotherapeutics to reduce the associated toxicities of chemotherapeutic agents in normal cells. The present article is focused on MDR development strategies in the cancer cell and different nanocarrier-based approaches in circumventing this hurdle to establish an effective therapy against deadliest cancer disease.
KW - Effective chemotherapy, tumor-targeted delivery
KW - Multidrug resistance
KW - Nano-delivery
KW - P-gp inhibition
UR - http://www.scopus.com/inward/record.url?scp=85064263939&partnerID=8YFLogxK
U2 - 10.1016/j.msec.2019.04.005
DO - 10.1016/j.msec.2019.04.005
M3 - Review Article
C2 - 31029353
AN - SCOPUS:85064263939
SN - 0928-4931
VL - 101
SP - 596
EP - 613
JO - Materials Science and Engineering C: Materials for Biological Applications
JF - Materials Science and Engineering C: Materials for Biological Applications
ER -